RT

Riju Tiwari

Active Director Additional Director DIN 11340209
DIN 11340209 First appointment Oct 2025 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2025
Shareholding value •••• Premium profile

About Riju Tiwari

Data last updated:

Riju Tiwari is an Additional Director at Nevit Pharma Private Limited (since 2025). The company operates in Trading. Nevit Pharma Private Limited reported revenue of ₹17.3 Lakh (FY 2024).

DIN 11340209
Primary Designation Additional Director
Industry Trading
First Appointment 15 Oct 2025
Largest company Nevit Pharma Private Limited · ₹17.3 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Nevit Pharma Private Limited U51909UP2022PTC169095
Additional Director15 Oct 2025₹17.3 Lakh (FY 2024)Active

Board colleagues of Riju Tiwari

Directorship timeline

Open interactive timeline →
Nevit Pharma Private Limited
Premium access

Shareholding and investment profile for Riju Tiwari

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Riju Tiwari

Riju Tiwari currently holds 1 directorship: Nevit Pharma Private Limited (Additional Director, since 15 Oct 2025, revenue ₹17.3 Lakh (FY 2024)).

Riju Tiwari was first appointed on 15 Oct 2025 as Additional Director at Nevit Pharma Private Limited.

The current boards of Riju Tiwari's companies include Brijesh Kumar Singh (Nevit Pharma Private Limited), Virendra Kumar Tiwari (Nevit Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available